Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Macular degeneration treatment

Ginkgo 1 2 151 million (36), 395.68 million (7) Age-related macular degeneration treatment, age-related memory impairment, altitude Antidepressant-induced sexual dysfunction, seasonal affective disorder, tinnitus... [Pg.10]

Tso and Lam suggested that astaxanthin could be useful for prevention and treatment of neuronal damage associated with age-related macular degeneration and may also be effective in treating ischemic reperfusion injury, Alzheimer s disease, Parkinson s disease, spinal cord injuries, and other types of central nervous system injuries. Astaxanthin was found to easily cross the blood-brain barrier and did not form crystals in the eye. [Pg.409]

There is no cure for age-related macular degeneration and the efficacy of most treatments is low. [Pg.935]

Drusen ablation may help patients with multiple large drusen in both eyes that have not progressed to neovascular macular degeneration. These laser treatments may lead to resolution of the drusen and improved visual acuity. However, it is not clear if progression to choroidal neovascular membranes and neovascular macular degeneration is reduced.23 There is a possibility that the laser treatments may induce choroidal neovascularization and retinal atrophy.22... [Pg.944]

There are no approved pharmacologic treatments for atrophic AMD. The Age-Related Eye Disease Study showed that a supplement containing ascorbic acid 500 mg, vitamin E 400 IU, beta carotene 15 mg, zinc oxide 80 mg, and cupric oxide 2 mg reduced the rate of clinical progression of all types of AMD by 28% in patients with at least intermediate macular degeneration. No benefit was seen in patients with earlier stages of age-related maculopathy however, the duration of the study may have been insufficient to detect this benefit.25... [Pg.944]

Comer GM, Ciulla TA, Criswell MH, Tolentino M. Current and future treatment options for nonexudative and exudative age-related macular degeneration. Drugs Aging 2004 21 967-992. Donahue SP, Khoury JM, Kowalski RP. Common ocular infections. A prescriber s guide. Drugs 1996 52 526-540. [Pg.947]

Donaldson, MJ and Pulido, JS, 2006. Treatment of nonexudative (dry) age-related macular degeneration. Curr Opin Ophthalmol 17, 267-274. [Pg.342]

Kijlstra, A, La Heij, EC, and Hendrikse, F, 2005. Immunological factors in the pathogenesis and treatment of age-related macular degeneration. Ocul Immunol Inflamm 13, 3-11. [Pg.345]

Radu, RA, Mata, NL, Nusinowitz, S, Liu, X, Sieving, PA, and Travis, GH, 2003. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt s macular degeneration. Proc Natl Acad Sci USA 100, 4742- 4747. [Pg.349]

The forms of phototherapy in common use include (i) the phototherapy of jaundice (neonatal hyperbilirubinemia) in the newborn, and especially in the prematurely born 5 (ii) the treatment of psoriasis using light in the UV-A range (320 100 nm) and an administered photosensitizer, such as 8-methoxypsoralen 6 (iii) the treatment of the wet form of age-related macular degeneration with a photosensitizer such as a benzoporphyrin derivative (VISUDYNE ), and a laser light source 7 and (iv) the treatment of certain cancers with a photosensitizer such as a porphyrin derivative, and red light.8... [Pg.946]

Compound (32) is currently being developed for the clinical treatment of cancer, of atherosclerotic vascular disease, and of age-related macular degeneration, all of which are PDT applications.132,133 Photodiagnostic applications also appear to be in view.141... [Pg.972]

Campa C, Harding SP (2011) Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets 12 173-181... [Pg.137]

Lucentis contains ranibizumab and is available for intravitreal injection. It is a vascular endothelial growth factor inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration. Unlike verteporfin, which is used in photodynamic treatment of age-related macular degeneration, ranibizumab does not require activation by local irradiation using non-thermal red light. [Pg.154]

A vitronectin (OvjSs integrin) antagonist, 267268, is currently undergoing clinical trials for the treatment of age-related macular degeneration. [Pg.334]

Other Localizations. Results of proton beam therapy for other tumor types and localizations have been reported, in particular, for retinoblastoma and age-related macular degeneration [2]. In the pioneering centers, patient selection, special care applied to each treatment, as well as expertise of the multidisciplinary clinical teams make it difficult to conclude whether the excellent results were due to the protons themselves or reflect the expertise of the different teams. [Pg.766]

See other pages where Macular degeneration treatment is mentioned: [Pg.403]    [Pg.403]    [Pg.405]    [Pg.407]    [Pg.409]    [Pg.243]    [Pg.715]    [Pg.476]    [Pg.403]    [Pg.403]    [Pg.405]    [Pg.407]    [Pg.409]    [Pg.243]    [Pg.715]    [Pg.476]    [Pg.84]    [Pg.604]    [Pg.1010]    [Pg.1256]    [Pg.762]    [Pg.205]    [Pg.953]    [Pg.159]    [Pg.132]    [Pg.163]    [Pg.454]    [Pg.335]    [Pg.509]    [Pg.534]    [Pg.22]    [Pg.198]    [Pg.322]    [Pg.121]    [Pg.461]    [Pg.1197]    [Pg.1272]    [Pg.1272]    [Pg.29]    [Pg.237]   
See also in sourсe #XX -- [ Pg.943 , Pg.944 ]



SEARCH



Macular

Macular degeneration

© 2024 chempedia.info